# Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder

> **NCT07093541** · — · AVAILABLE · sponsor: **Emalex Biosciences Inc.**

## Conditions studied

- Tourettes Disorder
- Tourette Disorder

## Interventions

- **DRUG:** ecopipam HCl ~2mg/kg/day

## Key facts

- **NCT ID:** NCT07093541
- **Lead sponsor:** Emalex Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07093541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07093541, "Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT07093541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*